Sernova, Seraxis Close $11.2M to Fund BetaNova Merger

Sernova Biotherapeutics Inc. and Seraxis Holdings, Inc. announced on Oct. 5, 2026 that they closed a US$11.2 million non-brokered convertible note financing tied to their proposed merger into BetaNova Biotherapeutics, Inc. The raise exceeds the US$10 million target the two companies had previously announced. Proceeds are earmarked for cGMP manufacturing of Seraxis' SR-02 allogeneic stem cell-derived pancreatic islet cells, patient enrollment for a Phase 1/2 type 1 diabetes trial in the fourth quarter, and first patient dosing in the first quarter of 2027.

Context — Why the BetaNova Financing Matters Now

The financing lands two days short of a month after Sernova and Seraxis signed their definitive merger agreement on Sept. 7, 2026. That agreement combines Seraxis' stem cell-derived pancreatic islet programs and its cGMP manufacturing platform with Sernova's Cell Pouch Bio-hybrid Organ. Upon completion, the two shareholder bases are expected to own roughly 50% of BetaNova each on a non-diluted basis.

The raise is the funding step the merger needed. Without it, the combined entity would have entered its clinical phase without the manufacturing runway to supply an allogeneic cell product at trial scale. Sernova management framed the close as the trigger for execution rather than a milestone in itself.

The round was led from inside. Sernova's chief executive Jonathan Rigby, chief financial officer James Parsons, chief commercial officer Marylyn Rigby and vice president of investor relations David Burke all participated. Seraxis president and CEO Will Rust and chief operating officer Carole Welsch also subscribed, alongside Dr. Steven Sangha and Arlo Investments.

Outside capital came from existing shareholders and new investors, though the report does not disclose how the $11.2 million splits between insiders and external buyers, nor the conversion terms, coupon or maturity of the notes. Noble Capital Markets is acting as exclusive financial advisor to Sernova on the merger, a mandate that predates the financing close.

For a clinical-stage regenerative medicine company, insider-heavy participation at the bridge stage is the signal that matters. It aligns the people who set the trial timeline with the capital that funds it, and it reduces the risk that the merger closes without a funded operating plan behind it.

Data — What the Numbers Show

The headline figure is the US$11.2 million raised against a US$10 million target, a 12% oversubscription. The instrument is a convertible note paired with common stock purchase warrants of Seraxis, issued without a broker. On completion of the merger, those notes are expected to convert automatically into BetaNova common stock.

Item	Detail
Financing size	US$11.2 million
Original target	US$10 million
Structure	Convertible notes plus warrants
Issuer	Seraxis Holdings, Inc.
Conversion	Automatic into BetaNova common stock on merger close

Before the raise, the target was US$10 million. After it, the committed amount is US$11.2 million, and the capital is allocated across five named workstreams rather than held as general corporate purpose.

The milestone schedule is unusually dense for a single financing. The company said it expects to enroll T1D patients in the fourth quarter, dose the first patient under an FDA-cleared investigational new drug application in the first quarter of 2027, and report initial clinical data in the first half of 2027. A Nasdaq listing readiness target is set for the first quarter of 2027, subject to listing requirements and approvals.

The report gives no peer comparison and no valuation for BetaNova. Sernova's shares trade on the Toronto Stock Exchange under SVA, on OTC markets under SEOVF, and on Frankfurt and Xetra under PSHO, but the report does not disclose any share price, market capitalization or financing valuation.

Analysis — What It Means for T1D Cell Therapy

The second-order effect runs through the type 1 diabetes cell therapy field, where the competitive question is no longer whether stem cell-derived islets can be made, but who can manufacture them at clinical grade and reach patients first. Sernova's chief executive said the company believes BetaNova is positioned to compete with other companies in the space by entering the clinic in the near term.

Manufacturing is the differentiator the deal is built around. Seraxis brings cGMP islet production; Sernova brings the Cell Pouch, an implantation device designed to hold and engraft functional pancreatic cells. Pairing a device with a cell product gives the combined company control over both halves of the delivery problem, which is where single-asset cell therapy developers often depend on third parties.

The immune-suppression question is the central scientific risk. Seraxis states that its mission is to demonstrate safety and potency of its islets in T1D patients without immune suppression therapy, and that SR-02 is paired with an immune tolerizing strategy. SR-03, the follow-on program, adds gene edits intended to increase host compatibility and potentially support long-term engraftment without immune suppression.

The counter-argument is timing. SR-03 remains preclinical, with an IND submission targeted for the second half of 2027, so the immune-evasion thesis is not what the current financing tests. SR-02 carries the near-term burden of proof, and the report offers no efficacy data, no patient numbers and no trial size.

Positioning follows the structure. Insiders and existing holders are long the conversion into BetaNova equity; new money is buying the same instrument at the bridge stage, ahead of a Nasdaq listing target that, if met, would widen the buyer base. The report does not state whether the notes were priced at a discount to any future round.

Outlook — What to Watch Next

The calendar is the story. Patient enrollment in the Phase 1/2 trial is targeted for the fourth quarter of 2026, first patient dosing for the first quarter of 2027, and initial clinical data for the first half of 2027. Each of those dates is a company expectation, not a completed event.

Two corporate catalysts sit alongside the clinical ones. Nasdaq listing readiness is targeted for the first quarter of 2027, subject to satisfaction of applicable listing requirements and approvals. Completion of the merger remains subject to required approvals and customary closing conditions, and the report gives no closing date.

On the pipeline side, the SR-03 gene-edited program is guided toward an IND submission in the second half of 2027. The report names no price levels, no trading ranges and no moving averages for any of the listed securities, so there are no technical thresholds to monitor. The watch items are approvals, enrollment and dosing, in that order.

Frequently Asked Questions

What does the BetaNova merger mean for Sernova shareholders?

On completion, Sernova and Seraxis shareholders are each expected to own approximately 50% of BetaNova on a non-diluted basis, per the report. Sernova shares currently trade on the TSX as SVA, on OTC as SEOVF and on Frankfurt and Xetra as PSHO. The merger still requires approvals and customary closing conditions, and the report does not state a closing date or exchange ratio.

What is SR-02 and how does it differ from SR-03?

SR-02 is Seraxis' lead allogeneic product, made of stem cell-derived pancreatic islet cells produced under cGMP processes and paired with an immune tolerizing strategy. SR-03 is the next-generation follow-on, which adds gene edits intended to increase compatibility with the host and potentially enhance long-term engraftment without immune suppression. SR-02 is the program entering the Phase 1/2 trial; SR-03 is targeted for an IND submission in the second half of 2027.